Open Innovation Shouldn't Be a Hard Sell. But, All Too Often, It Is.
At Ezassi, we believe whole-heartedly in the importance of Open Innovation for the survival of businesses. That being said, we also fully recognize that convincing decision makers to go forward with Open Innovation initiatives can be a hard sell. It almost seems counterintuitive that the same leaders who were responsible for launching and cultivating a successful business, would be resistant to change even in the face of evolving markets. Yet all too often, that is the case. Open Innovation convincing decision makers should be a primary focus.
This means that it falls on employees to make the case for Open Innovation and convincing the decision makers, which can be a thin line to walk. To help you navigate these choppy waters, we put together a comprehensive guide entitled, “How to Make Open Innovation an Easy Sell in Your Organization,”...
Intellectual Property (IP) Protection is the biggest obstacle to an effective, sustained open innovation initiative. IP protection is complicated because both the company and potential contributors have developed concepts and systems, and sharing them brings risks unless tools are in place to protect it. The challenge is to balance these competing IP needs to assure a continual flow of quality submissions. Ezassi has IP protection built into our robust Idea & Open Innovation Management Solution, allowing organizations to confidently maximize the benefits of an OI system.
The Need for IP Protection for Open Innovation
Intellectual Property protection is necessary to Open Innovation for three reasons:
Trust. Open Innovation requires the development of a symbiotic relationship between the Corporation and its contributors. For this to occur, there must be trust between the parties that their IP will not be exploited by the other. An effective IP protection establishes the trust environment.
Reputation. Companies must have...
Pharmaceutical Accelerate Innovation with Software Technology
First, A Look at Deloitte's US Life Sciences Outlook Report
Deloitte released the 2017 US Life Sciences Outlook and the report discusses some very important points for the pharmaceutical sector to consider. It’s a great report and one worth reading. Let’s compound this with a few other events occurring in this space:
The healthcare bill on the senate floor that’s yet to be determined.
The more informed consumers that think nothing of taking to social media to complain about the cost of care and drug prices.
The press and evening news reporting immediately on the fallout from social media and drug prices.
High deductible plans continue to trend upwards which equates to more consumers paying more out of their wallet for healthcare.
And then there's Amazon...
CIMdata Publishes Enterprise Innovation Management Solutions Landscape — Connecting the Dots
[vc_row][vc_column][qodef_button size="" type="solid" hover_animation="" target="_blank" icon_pack="" font_weight="" text="View Report" link="http://ezassi.wpengine.com/enterprise-innovation-management-solutions-white-paper-ezassi-cimdata.pdf" font_size="16"][/vc_column][/vc_row]
eZassi Participates in CIMdata's Enterprise Innovation Management Solutions Landscape Report Findings
CIMdata recently published this report, eZassi participated in the report findings, providing insight, commentary, discovery and suggestions to aide in guiding enterprise organizations with connecting the dots of enterprise innovation management (EIM).
Expectation of Industrial Companies and Next Gen Enterprise Innovation Management Solutions
CIMdata expects, from this report, “that industrial companies will become more familiar with enterprise innovation enabling technologies and will feel more prepared to invest in the next generation of solutions that are designed to increase their ability to innovate more effectively and sustainably.”
CIMdata incorporated thought-leadership interviews and briefings with four (4) solution providers, including eZassi, and subsequently conducted interviews with chief innovation executives for seven (7) large enterprises, including:
Plastics Today interview with eZassi's CEO, Peter von Dyck, discusses how the Medical Device Industry (MedTech Industry) is opening up to embracing open innovation. The medtech industry open innovation challenges have been on the forefront of the industry for a long time. This interview highlights the known challenges and what is happening with medtech open innovation.
Below are a few highlights from this discovery article and interview:
The medtech industry is well-known for wanting to keep innovation internal but times are changing. Companies, like those in medtech, feel it is a must to open up their innovation strategy to be competitive in the marketplace.
Open innovation in a secure environment is not so scary. eZassi Open Innovation Management Software solution provides a valuable component for clients that need that extra level of security. Open Innovation with IP Protection.
Similar to the scariness of e-commerce with trusted online transaction now it's safe for business to...
John R. Harris is a senior partner in the Technology/Intellectual Property Practice of Morris, Manning, & Martin, LLP, and a registered patent attorney. For 35 years, Mr. Harris has advised clients in the electronics, manufacturing, medical devices, financial services, software, computer, and Internet industries on intellectual property and other technology-related legal matters. He is a graduate of Georgia Tech, Emory Law School, and the Goizueta Business School at Emory University.
In this video clip John talks about open innovation and external intellectual property concerns.